BHST
BioHarvest Sciences Inc. (BHST) SWOT Analysis Analysis (2026)
No material changes this month.
Strengths
Liquidity is solid with a 2.24 current ratio and 1.75 quick ratio, leaving BHST better positioned than more levered peers to absorb working-capital shocks.
Net debt to EBITDA is slightly negative, indicating a net cash position that compares favorably with indebted peers and supports financial flexibility.
Capital intensity appears manageable relative to peers because the balance sheet can fund operations without immediate refinancing pressure, despite weak current returns.
The company’s cash conversion cycle is long at 119 days, but the absence of acute liquidity stress suggests peers with tighter working-capital profiles face greater near-term strain.
Weaknesses
Return on invested capital is -17.1%, showing BHST destroys value versus profitable peers and signaling structurally weak capital efficiency.
The 119-day cash conversion cycle ties up cash for longer than better-run peers, which suppresses reinvestment capacity and margin resilience.
Debt to equity of 0.89 is not extreme, but it is less conservative than net-cash peers and reduces downside flexibility if operating performance weakens.
Missing evidence of positive operating or gross margins leaves BHST looking weaker than peers with clearer scale or pricing advantages.
Opportunities
If BHST shortens its 119-day cash conversion cycle, it could release working capital faster than peers and improve funding capacity without external capital.
A net cash balance gives BHST more room than leveraged peers to invest in process improvements that could lift returns and operating efficiency.
Relative balance-sheet flexibility may allow BHST to outlast weaker competitors during demand softness, improving competitive positioning over a 2–5 year horizon.
Any improvement in asset utilization would have outsized impact because the current negative ROIC leaves BHST starting from a low base versus peers.
Threats
Persistent negative ROIC threatens BHST’s competitive standing because peers generating positive returns can compound capital while BHST erodes it.
A long cash conversion cycle increases exposure to inventory or receivables slippage, leaving BHST more vulnerable than peers with faster cash turnover.
If operating performance stays weak, the current leverage profile could become less comfortable than net-cash peers, narrowing strategic flexibility.
Peers with stronger margins and faster working-capital turns can reinvest more aggressively, which may widen BHST’s relative gap over time.
Overall Score
BHST’s balance sheet is comparatively resilient, but negative returns on capital and slow cash conversion leave its structural positioning weaker than stronger-performing peers.
Sources
- Company filings (10-K, 10-Q, investor presentations)
- Financial and market data providers
- Public news and industry information
🔒 Go Beyond This Framework
This is one of 10 institutional-grade frameworks Invetso runs on BioHarvest Sciences Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.
